An improved dressing is presented which enables quicker wound closure and a lower anesthesia requirement, comprised of an improved prior-art skin-substitute. The improvements consist of variations in the thickness of the woven portion of the dressing, to increase wound adherence.

The present invention relates to absorbent articles for solving the problem of stopping the excessive accumulations of sweat from building up inside a prosthetic liner. The four layers of materials include: a first layer of a cellulose pulp material having a thickness use for a desired absorbency, a second layer of a wicking cloth material having a thickness use for a desired absorbency, a third layer of a non-toxic double side adhesive tape material one side will stick to both layer, and a fourth layer that is the opposite side which are cover with paper material that can be peeled from the third layer to adhere the inside of a prosthetic liner base sheet to stop the excessive accumulation build-up of sweating.

Methods, copolymer materials and devices are provided for embolic arterial interventions (embolization therapy or embolotherapy). More particularly, radiopaque, bioresorbable spherical microparticles for embolization or vascular occlusion therapies, comprising copolymers of iodine-containing, halogenated phenyl-containing units, such as iodinated desaminotyrosine derivatives, and rubbery components, such as polyethylene glycol (PEG), polycaprolactone (PCL), polytetramethylene oxide (PTMO) or polytrimethylene carbonate (PTMC), are provided. The provided microbeads may further contain, or be coated with, therapeutic agents such as paclitaxel, for targeted delivery of the therapeutics.

A microneedle device for delivering therapeutic ingredients to the dermis or epidermis. The device contains biodegradable microneedles, which extend from a backing, and are sandwiched between a cap film and a film which is coextensive with the tips of the microneedles and the spaces on the backing between the microneedles.

Methods and compositions for treatments associated with endovascular grafts, dissections, peripheral aneurysms, and neuro aneurysms are provided that deliver 1,2,3,4,6-pentagalloyl glucose (PGG) or analogues or derivatives thereof and/or LeGoo®. Also provided is a device to deliver 1,2,3,4,6-pentagalloyl glucose (PGG) or analogues or derivatives thereof or LeGoo® to the tissue to be treated.

Hygienic Hydrophilic coatings, hydrophilic coating formulations and wetting fluids that include an anti-infective agent.

Described herein is a composition for submucosal injection comprises a biocompatible modified starch and a pharmaceutically acceptable carrier for injection. The biocompatible modified starch is in an amount ranging from 0.2 wt % to 50 wt % of the total weight of composition. The biocompatible modified starch is selected from one or more of the group consisting of: etherified starches, esterified starches, cross-linked starches, pre-gelatinized starches, graft starches and composite modified starches, which has a molecular weight ranging from 3,000 to 2,000,000 daltons, a water absorbency capability of at least twice of its own weight, and a particle size from 500 nm to 1000 μm. The viscosity of the composition ranges from 9 mPa.Math.s to 150,000 mPa.Math.s at 25° C. The present disclosure also provides a combination reagent for submucosal injection, comprising the above-mentioned biocompatible modified starch and the pharmaceutically acceptable carrier for injection.

Hygienic Hydrophilic coatings, hydrophilic coating formulations and wetting fluids that include an anti-infective agent.

A vascular device for insertion in a body lumen, wherein the device includes a surface including at least a portion that is a functionalized surface provided with double or more charged ions such that the ions are exposed to a bodily fluid when the vascular device is inserted in the body lumen. The vascular device allows for reducing complications in its use and, particularly, for improving a desired healing in the body and preventing restenosis. At the same time, it allows for being manufactured at comparably low effort and for a convenient handling.

A medical device substrate with a coating including a functional layer located on the substrate, with the functional layer including at least one sugar alcohol and being bonded to the substrate directly or indirectly via a functionalization of the sugar alcohol. Alternatively, the functional layer may also include other saccharides, in which case it is essential that polymerization of the saccharides takes place only upon bonding to the substrate. The inventive medical device exhibits reduced platelet adhesion and aggregation.